The global Inhaled Nitric Oxide Delivery Systems market was valued at USD 247.5 million in 2020 which expected to reach USD 434.2 million by 2027 at a CAGR 6.9% from 2020-2027.
Inhaled Nitric Oxide (NO) Delivery Systems are medical devices that give nitric oxide to patients who have severe breathing issues. Nitric oxide is therapeutically effective in dilating blood vessels and relaxing muscular tension in order to efficiently absorb oxygen in the body. Furthermore, nitric oxide delivery systems are employed to treat neonates with hypoxic respiratory failure.
Get Sample Copy of this Report @ https://qualiketresearch.com/request-sample/Inhaled-Nitric-Oxide-Delivery-Systems-Market/request-sample
Ongoing RD activities resulting in new application areas in the healthcare industry are projected to present profitable prospects for the expansion of the global inhaled nitric oxide market. On January 30, 2020, the World Health Organization (WHO) declared the COVID-19 outbreak a public health emergency of worldwide significance. COVID-19 has affected approximately 210 nations worldwide.
The rise in the prevalence of respiratory disorders such as COPD and asthma may also be too responsible for the quick growth of the global inhaled nitric oxide delivery system market.
Impact of COVID-19
In the United States, approximately 1.8 million people are infected with coronavirus as of May 2020. Furthermore, the US FDA has approved the emergency use of VERO Biotech's GENOSYL NO delivery device in urgent COVID-19 patients suffering from respiratory failure. These developments are projected to increase the demand for inhaled nitric oxide delivery devices in the country.
The Global Inhaled Nitric Oxide Delivery Systems Market is segmented into Type, End-user, Distribution Channel and Growing System. By Type such as Pediatrics, Adult. Further, market is segmented into By End-user such as Hospitals, Ambulatory Centers, and Clinics.
Global Inhaled Nitric Oxide Delivery Systems Market is segmented into five regions such as North America, Latin America, Europe, Asia Pacific, and Middle East Africa. North America has the largest market share and Regional growth is boosted by an increase in the use of INO therapy, a favorable government initiative, and the presence of advanced medical infrastructure. APAC, on the other hand, had the highest revenue share in 2020 and is expected to maintain this trend during the projection period due to the expanding pediatric population.
Various key players are listed in this report such as Mallinckrodt Pharmaceuticals; Getinge; Vero Biotech; LINDE; Beyond Air; NU MED; Bellerophon Therapeutics; Air Liquide Healthcare; Circassia Pharmaceuticals.
- Ambulatory Centers
- North America
- Latin America
- Asia Pacific
- Middle East Africa
Browse Full Research Report @ https://qualiketresearch.com/reports-details/Inhaled-Nitric-Oxide-Delivery-Systems-Market
QualiKet Research is a leading Market Research and Competitive Intelligence partner helping leaders across the world to develop robust strategy and stay ahead for evolution by providing actionable insights about ever changing market scenario, competition and customers. QualiKet Research is dedicated to enhancing the ability of faster decision making by providing timely and scalable intelligence. We use different intelligence tools to come up with evidence that showcases the threats and opportunities which helps our clients outperform their competition.
Research Support Specialist
6060 N Central Expy #500, TX 75204, U.S.A